欧林生物：公司已经以破伤风疫苗推广体系为基础，构建了面向临床场景的成熟推广网络

Core Viewpoint - The company is focusing on the clinical application of the recombinant goldenseal vaccine, leveraging its existing promotion network established through the tetanus vaccine [1] Group 1: Clinical Application and Promotion Strategy - The primary use case for the recombinant goldenseal vaccine is clinical application [1] - The company has built a mature promotion network based on the tetanus vaccine promotion system [1] - The company plans to apply the successful experience from the tetanus vaccine to the recombinant goldenseal vaccine [1] Group 2: Market Education and Support - The company aims to support academic research and market education to standardize in-hospital diagnostic processes [1] - This initiative is intended to help reduce antibiotic-resistant bacterial infections [1] - The company is committed to ensuring efficient commercialization of the vaccine [1] Group 3: Sales and Promotion Activities - The sales team will initiate preliminary promotion activities based on the product application status of the recombinant goldenseal vaccine [1]